scholarly journals Pharmaceutical supply chains in Africa – overcoming unique transport security challenges

2014 ◽  
Vol 7 (4) ◽  
pp. 333-337 ◽  
Author(s):  
Bryan Goshorn ◽  
Craig Usswald
Keyword(s):  
Supply Chains ◽  
Security Challenges ◽  
Pharmaceutical Supply Chains

scholarly journals Can global pharmaceutical supply chains scale up sustainably for the COVID-19 crisis?

2020 ◽  
Vol 159 ◽  
pp. 104868 ◽  
Author(s):  
Derrick Ethelbhert C. Yu ◽  
Luis F. Razon ◽  
Raymond R. Tan
Keyword(s):  
Supply Chains ◽  
Scale Up ◽  
Pharmaceutical Supply Chains

scholarly journals Development of a service quality scale for pharmaceutical supply chains

2009 ◽  
Vol 3 (1) ◽  
pp. 26-45 ◽  
Author(s):  
Niaz Ahmad ◽  
Muhammad Usman Awan ◽  
Abdul Raouf ◽  
Leigh Sparks
Keyword(s):  
Service Quality ◽  
Supply Chains ◽  
Quality Scale ◽  
Pharmaceutical Supply Chains

scholarly journals EU POLICY AGAINST FALSIFIED MEDICINES: OPTIONS FOR FURTHER DEVELOPMENT

2020 ◽  
Vol 1 ◽  
pp. 147-153
Author(s):  
Krasimira Valcheva
Keyword(s):  
Supply Chains ◽  
Pharmaceutical Companies ◽  
The European Union ◽  
Effective Prevention ◽  
Patient Protection ◽  
Regulatory Frameworks ◽  
Falsified Medicines ◽  
Pharmaceutical Supply Chains ◽  
National Governments ◽  
Further Development

The globalization of trade and internet access significantly increased the health risks associated with falsified medicines. International organizations, pharmaceutical companies and national governments developed a wide variety of measures to combat their pervasive penetration into the legal supply chains. However, the lack of harmonization, broad acceptance and legally bound enforcement obstructed their endeavours. The unsatisfying outcomes resulted in enhanced supranational cooperation focused on strengthening the pharmaceutical regulatory frameworks and the improvement of patient protection.  In 2011 the European Union joined the global fight with the adoption of Directive 2011/62/EU that became known as the Falsified Medicine Directive. It is legally binding for Member States and amends the fundamental for the pharmaceutical sector Directive 2001/83/EC. The objective of the present paper is to verify if it represents a comprehensive tool for effective prevention of the access of falsified medicines in the European legal pharmaceutical supply chains. The results revealed that although it is rather detailed, there are areas that could be further developed and improved when compared to analogical policies and initiatives.

Sign in / Sign up

Export Citation Format

Share Document